Onesource Specialty Pharma Limited — Updates, 05-05-2025: Press Release

OneSource is gaining strong traction with Q4 revenue up 22% YoY to ₹426 Cr and EBITDA jumping 79% to ₹183 Cr, led by high-margin Drug Device Combinations and Biologics. FY25 revenue rose 30% to ₹1,445 Cr, and EBITDA more than doubled to ₹467 Cr, pushing margins up 11 percentage points to 32%. PAT turned positive at ₹93.6 Cr from a prior loss. Growth is fueled by 39 new RFPs/licensing deals, half from existing clients, and synergies from recent acquisitions enhancing cross-selling and efficiency.